Myriad Genetics

Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to assess an individual's risk of developing a disease later in life. The Other segment offers testing products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients, and also includes corporate services. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Myriad Genetics reports robust Q4 growth and eyes market expansion

Myriad Genetics showcased strong revenue growth and strategic initiatives to drive profitability in Q4 2022.
The company's focus on customer engagement, product volumes, and market positioning reflects a commitment to growth and operational excellence.
Challenges in managing competition and optimizing operational efficiency are balanced by opportunities for revenue growth and market expansion.

Myriad Genetics reports strong Q1 earnings, eyes profitability in Q4

Myriad Genetics demonstrated robust performance in Q1, leveraging strategic partnerships and operational improvements to drive revenue growth and enhance testing volumes.
While facing challenges like billing issues and seasonality-related declines, the company remains focused on core products, profitability, and growth opportunities.
With a strong financial outlook, emphasis on innovation, and commercial initiatives, Myriad Genetics is well-positioned to capitalize on market opportunities and drive sustainable growth.

Myriad Genetics reports solid Q2 growth and strategic focus

Myriad Genetics showcased strong financial performance, operational efficiencies, and strategic focus on growth and profitability.
While facing challenges like milestone payment concerns and industry competition, the company's strengths in key segments and operational capabilities position them well.
Opportunities in product enhancements, channel expansions, and investor engagement pave the way for continued success and market leadership.

Myriad Genetics reports strong Q3 earnings and raises 2024 guidance

Myriad Genetics reported strong revenue growth and operational improvements, with a focus on key product lines and enhancing customer experience.
The company raised financial guidance for 2023 and introduced revenue guidance for 2024, showcasing confidence in achieving long-term growth targets.
Challenges include regulatory changes, market penetration, and maintaining profitability amidst competitive dynamics, while opportunities lie in sustained growth and revenue optimization.
Overall, Myriad Genetics demonstrated resilience and strategic focus in driving growth, improving margins, and navigating market challenges effectively.

Myriad Genetics reports strong Q4 performance and eyes market expansion

Myriad Genetics delivered a strong Q4 performance with a focus on growth, strategic investments, and operational improvements. The company faces challenges in pricing and reimbursement but sees opportunities in market expansion and new product launches. Overall, Myriad Genetics is optimistic about its future prospects and market positioning.

Myriad Genetics reports robust Q1 performance and eyes growth opportunities

Myriad Genetics delivered a strong quarter with revenue growth and positive EBITDA, focusing on strategic areas like oncology and women's health. The company is optimistic about exceeding guidance but remains cautious. Analysts raised inquiries about various segments and operational decisions, with the company emphasizing profitable growth and maintaining margins.

Myriad Genetics reports strong Q2 performance and raises revenue targets

Myriad Genetics delivered a robust Q2 performance with revenue growth, positive earnings, and strategic wins in payer coverage, setting the stage for continued growth.
The company's focus on efficiency, customer satisfaction, and profitable growth positions it well for future success amidst market challenges and opportunities.
With raised revenue targets, expanded market acceptance, and operational excellence, Myriad Genetics demonstrates resilience and adaptability in a dynamic healthcare landscape.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nationwide search for permanent successor underway Nationwide search for permanent successor underway

Myriad Genetics Chief Scientific Officer Jerry Lanchbury Retires after 19 Years of Service

Investors are optimistic about Myriad Genetics (MYGN), given robust volume growth for GeneSight and prenatal testing.

Here's Why You Should Hold on to Myriad Genetics (MYGN) for Now

SALT LAKE CITY, Dec. 15, 2021 (GLOBE NEWSWIRE) -- Now is the time when people start to think of new year's resolutions to improve their health. For many, the focus is on physical goals like losing weight or exercising more. A nationwide survey suggests that many may want to consider adding mental health resolutions to their list.

New Year's Resolutions: Americans Say Body & Mind Equally Important in Theory but Not in Practice, According to GeneSight® Mental Health Monitor Nationwide Survey

GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challenge GeneSight Mental Health Monitor finds many parents struggle to know the difference between teenage behavior and a mental health challenge

The New Generation Gap: Nationwide Survey Finds Different Perspectives on Anxiety Between Parents, Young Adults

SALT LAKE CITY, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced the promotion of Nicole Lambert to chief operating officer (COO). In her new role, she will continue to report directly to Paul J. Diaz, president and CEO, Myriad Genetics.

Myriad Genetics Promotes Nicole Lambert to Chief Operating Officer

SALT LAKE CITY, Nov. 22, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced two upcoming poster presentations at the 2021 San Antonio Breast Cancer Symposium (SABCS) that showcase the importance of genetic testing and precision medicine as integral components of both breast cancer treatment recommendations and risk assessment.

Myriad Genetics to Present New Data at San Antonio Breast Cancer Symposium Highlighting Value of Genetic Testing in Breast Cancer Risk Assessment and Treatment

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment drove Q3 sales despite a challenging business environment.

Myriad Genetics (MYGN) Q3 Loss Wider Than Expected, Revenues Top

Myriad Genetics, Inc. (MYGN) CEO Paul Diaz on Q3 2021 Earnings Call Transcript

Myriad (MYGN) delivered earnings and revenue surprises of -300.00% and 1.80%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Reports Q3 Loss, Tops Revenue Estimates

Myriad Genetics Reports Third Quarter 2021 Results, Continues Strong Execution of Strategic Growth & Transformation Plans

SALT LAKE CITY, Oct. 27, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended September 30, 2021, at 4:30 p.m. EDT on Tuesday, November 2, 2021. The company's quarterly earnings will be released the same day prior to the market opening. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics' performance for the third quarter of 2021.

Myriad Genetics to Release Third Quarter Financial Results on November 2, 2021

New legal leader brings healthcare expertise from Quest Diagnostics and experience at major global law firms New legal leader brings healthcare expertise from Quest Diagnostics and experience at major global law firms

Myriad Genetics Names Pamela Wong as Chief Legal Officer

SALT LAKE CITY, Oct. 11, 2021 (GLOBE NEWSWIRE) -- Many Americans are experiencing anxiety symptoms as a result of the pandemic. Yet, one in five say they won't seek treatment for mental health conditions and others say they won't get help until these symptoms take a toll in their lives.

Americans' anxiety impacted by the ongoing pandemic, yet 1 in 5 say they won't seek treatment according to the GeneSight® Mental Health Monitor nationwide survey

Investors are optimistic about Myriad Genetics (MYGN) owing to strong testing volume growth and notable product launches.

Here's Why You Should Retain Myriad Genetics (MYGN) for Now

Nicole Lambert, Corporate Officer at Myriad Genetics (NASDAQ:MYGN), made a large insider sell on September 27, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Monday showed that Lambert sold 14,849 shares of Myriad Genetics at prices ranging from $33.10 to $33.31.

Myriad Genetics Insider Sold Over $None In Company Stock

SALT LAKE CITY, Sept. 13, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it has completed the sale of select operating assets and intellectual property (IP), including the Vectra® test, from Myriad Genetics' autoimmune business unit to Labcorp (NYSE: LH) for $150 million in cash. Labcorp is a leading global life sciences company and one of the nation's largest laboratory service providers.

Myriad Genetics Completes Sale of Myriad Autoimmune's Vectra Testing Business to LabCorp

SALT LAKE CITY, Sept. 08, 2021 (GLOBE NEWSWIRE) -- Depression medication trial and error is far too common – and may result in additional mental health challenges.

Only 8% of people remain hopeful after depression medication fails them, according to GeneSight® Mental Health Monitor nationwide survey

Strength in Myriad Genetics' (MYGN) Molecular Diagnostic segment has managed to drive Q2 sales despite a challenging business environment.

Myriad Genetics (MYGN) Q2 Earnings Beat, Gross Margin Rises

Myriad Genetics' (MYGN) CEO Paul Diaz on Q2 2021 Results - Earnings Call Transcript

Myriad Genetics, Inc. (NASDAQ:MYGN) shares are trading higher by 12.4% at $34.68 Tuesday afternoon after the company reported better-than-expected fourth-quarter EPS and sales results. Myriad Genetics reported quarterly earnings of 12 cents per share which beat the analyst consensus estimate of a loss of 7 cents per share.

What's Up With Myriad Genetics Shares Trading Higher Tuesday?

The stock price of Myriad Genetics, Inc. (NASDAQ: MYGN) increased by over 13% during intraday trading. This is why it happened.

MYGN Stock Price Increases Over 13% Intraday: Why It Happened

Myriad (MYGN) delivered earnings and revenue surprises of 271.43% and 13.60%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Myriad Genetics (MYGN) Beats Q2 Earnings and Revenue Estimates

SALT LAKE CITY, Aug. 03, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced financial results for its second quarter ended June 30, 2021 and provided an update on recent business performance and strategic transformation plans.

Myriad Genetics Delivers Strong Revenue and Earnings Growth in June 2021 Quarter, Continues to Execute on Strategic Growth & Transformation Plans

SALT LAKE CITY, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Advancing its mission to expand access to genetic testing, Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today launched a new version of its market-leading MyRisk Hereditary Cancer Test. For the first time, women of all ancestries can now receive a personalized polygenic breast cancer risk assessment together with the market's most accurate hereditary cancer test.

Myriad Genetics Expands Access to Genetic Testing with Launch of First Polygenic Breast Cancer Risk Assessment Score Validated for Women of All Ancestries

SALT LAKE CITY, July 28, 2021 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that it will hold its quarterly earnings conference call for the quarter ended June 30, 2021, at 4:30 p.m. EDT on Tuesday, August 3, 2021. The company's quarterly earnings will be released prior to the market opening on August 3, 2021. During the call, Paul J. Diaz, president and CEO, and R. Bryan Riggsbee, chief financial officer, will provide a financial overview and business update of Myriad Genetics' performance for the second quarter of 2021.

News for Myriad Genetics Stock (MYGN)